New Taipei City, Taiwan, Nov. 24, 2025 — Jyong Biotech Ltd. (Nasdaq: MENS), referred to as “the Company” or “Jyong Biotech,” a Taiwan-based, science-focused biotechnology firm dedicated to developing and commercializing innovative, differentiated plant-derived drugs, primarily for urinary system diseases, with an initial market focus on the U.S., EU, and Asia, announced today that it has signed a non‑binding letter of intent (the “LOI”) with a South Korean pharmaceutical company. The LOI’s purpose is to review and assess the potential in‑licensing and subsequent development of Jyong Biotech’s plant-derived drug, MCS-2, specifically for the Korean market. The prospective South Korean partner is a well-known provider to both general hospitals and clinics, and the LOI signifies a mutual interest in evaluating the commercial and regulatory avenues for launching MCS products in Korea.
This initiative aligns with Jyong Biotech’s co‑commercialization strategy, which involves partnering with regional entities possessing established sales networks and localized regulatory proficiency. The parties are currently negotiating definitive terms. If these terms are finalized, the partnership would aim to utilize the partner’s commercial infrastructure to accelerate market penetration and patient access within Korea. The LOI is non‑exclusive and is contingent upon standard due diligence, regulatory approval, the negotiation of definitive agreements, and other customary closing conditions.
Fu Feng Kuo, Chairwoman of Jyong Biotech, stated: “Our selective co‑commercialization strategy with strategic partners will enable broader and more rapid patient access. This is achieved by integrating our product development capabilities with our partners’ commercial reach and local market insights. The Company is committed to advancing LOI negotiations with these strategic partners and will provide updates as significant developments occur.”
Currently, MCS-2 remains an investigational new drug candidate and has not received approval for commercial use in any jurisdiction. Jyong Biotech will adhere to all applicable regulatory disclosure requirements and will provide timely, accurate, and comprehensive updates regarding material developments.
About Jyong Biotech Ltd.
Jyong Biotech Ltd., headquartered in Taiwan, is a science-driven biotechnology company focused on the development and commercialization of innovative, distinct plant-derived new drugs. Its primary specialization is in the treatment of urinary system diseases, with initial markets targeted in the U.S., EU, and Asia. Since its establishment in 2002, the Company has cultivated integrated capabilities covering all critical aspects of drug development, including early-stage drug discovery, clinical trials, regulatory affairs, manufacturing, and commercialization. By leveraging robust research and development capacities and a proprietary platform, Jyong Biotech has been advancing a portfolio of botanical drug candidates, including its lead candidate, BOTRESO®, another botanical drug candidate in clinical stages, and several preclinical-stage botanical drug candidates. The Company strives to develop and deliver top-tier innovative drugs to address customer health needs and aims to be a respected and valuable business organization.
For more information, please visit: , .
Forward-Looking Statement
This press release contains statements that are forward-looking. Such statements encompass plans, objectives, goals, strategies, future occurrences or performance, and underlying assumptions, as well as any statements that are not historical facts. When the Company employs terms such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not pertain solely to past events, it is making forward-looking statements. These forward-looking statements do not guarantee future performance and are subject to risks and uncertainties that could cause actual outcomes to differ substantially from the Company’s expectations expressed in these statements. These statements are exposed to uncertainties and risks, including but not limited to, those related to market conditions and other factors detailed in the “Risk Factors” section of the Company’s registration statement, prospectuses, annual and interim reports, and other filings with the SEC. For these reasons, among others, investors are advised against placing undue reliance on any forward-looking statements in this press release. Further factors are discussed in the Company’s SEC filings, which are accessible at www.sec.gov. The Company assumes no obligation to publicly amend these forward-looking statements to reflect events or circumstances arising after the date of this document.
For more information, please contact:
Jyong Biotech Ltd.
Investor Relations
WFS Investor Relations Inc.
Email:
Phone: +1 628 283 9214
